Denied at the Pharmacy? What to Do About Medicare's New $50 GLP-1 Bridge

Dolores called me on a Tuesday afternoon, and I could hear the crackle in her voice before she said a single word about the pharmacy.

She'd driven twenty minutes to pick up her first month of Wegovy. Her doctor had told her about the new Medicare Bridge — fifty dollars, he'd said, just fifty for a month's supply of a drug that would otherwise cost her more than her water heater. She'd budgeted the fifty. She'd brought exact change, the way her mother taught her. And the young man behind the counter looked at his screen, frowned, looked again, and told her the claim came back rejected. No medication. No explanation she could hold onto. Just "your insurance won't cover it," and a line of people forming behind her.

"Eleanor," she said, "did I do something wrong? Did I misunderstand?"

She hadn't done a single thing wrong. And if you or someone you love has stood at that counter in these first weeks of July, expecting fifty dollars and walking out with nothing, I want you to hear me clearly: this is almost never what it looks like. Let me walk you through the whole thing — what this Bridge is, who it's for, and exactly what to do when the register says no.

What the GLP-1 Bridge Is, and Why It Exists

The Medicare GLP-1 Bridge is a short-term demonstration program from CMS — the folks who run Medicare. It opened July 1, 2026, and it's scheduled to run through December 31, 2027. That's it. A bridge, by design, from one shore to another, meant to carry people across a gap for a defined stretch of time.

Here's the gap it's carrying us over. For years, standard Part D law simply could not cover GLP-1 drugs when they were prescribed for weight loss. If your doctor wrote it for diabetes, fine. For weight management alone? Medicare's hands were tied. So millions of older adults who could genuinely benefit from these medications were staring at list prices north of a thousand dollars a month, and quietly deciding they'd make do without.

The Bridge changes that — temporarily. It lets eligible Part D enrollees get certain GLP-1 drugs, prescribed specifically for weight management, at a flat copay. The manufacturers who chose to participate supply the drug at a net price of $245 for a monthly supply, which is part of why nobody's calling this permanent coverage. It's a demonstration. An experiment with a clock on it. But for the eighteen months it runs, it's a real door opening for a lot of people who'd been shut out.

Who Actually Qualifies

This is where I want us to slow down, because the eligibility rules have a wrinkle in them that's tripping people up.

There are three ways in.

Path one: a BMI of 35 or higher at the time your GLP-1 therapy was started.

Path two: a BMI of 30 or higher at the time therapy started, plus one of these — heart failure, high blood pressure that stays high even on two or more medications, or chronic kidney disease (stage 3a or higher).

Path three: a BMI of 27 or higher at the time therapy started, plus a diagnosis of one or more of these — pre-diabetes (which the American Diabetes Association defines as an A1C between 5.7% and 6.4%), a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.

On top of that, you also have to be 18 or older, and the drug has to be prescribed for weight reduction and maintenance alongside ongoing lifestyle changes — real attention to nutrition and physical activity, the way the FDA label describes. Your prescriber attests to all of this on a prior-authorization form. You don't fill it out yourself; your doctor does.

Now, the wrinkle. The BMI is measured at the time therapy was started, not where you stand today. I've seen this one already confuse good people. Say you began a GLP-1 back in September of 2024 at a BMI of 37, and the medication has done its quiet work, and today you're at 34. You still qualify. Your prescriber attests that you met the BMI-35 threshold when you began. The whole point would collapse if the program punished you for the very success it's meant to support — so it doesn't.

If you're not certain what your BMI was at initiation, that's a perfectly good question for your prescriber's office. They have it in the chart.

Which Drugs Count — and Which Don't

This part matters enormously, because two of the most famous names in this whole conversation are not on the list.

Covered:

• Foundayo (orforglipron) — Eli Lilly's oral GLP-1 pill, FDA-approved April 1, 2026. All formulations.
• Wegovy (semaglutide) — both the injection and the oral tablet. All formulations.
• Zepbound (tirzepatide) — but only in the KwikPen formulation. The single-dose vials and pens of Zepbound are not covered.

Not covered: Ozempic and Mounjaro. I know. These are the names everyone recognizes. But both are FDA-approved for Type 2 diabetes, not for weight loss, so they fall outside what the Bridge was built to do. If you've been taking Ozempic or Mounjaro off-label for weight, that's a conversation to have with your doctor about whether switching to a Bridge-eligible drug makes sense for you. Don't stop anything on your own — just bring it up at your next visit.

If you're just beginning one of these medications, I'd gently point you toward a companion piece I wrote on protecting your muscle and bone while on a GLP-1. These drugs work, but they can take more than fat with them if you're not paying attention to protein and movement, and we don't want to trade one problem for another.

The Exclusion That Confuses People

Here's a twist that feels backwards until you see the logic.

If your GLP-1 is prescribed for Type 2 diabetes, for moderate-to-severe obstructive sleep apnea, or for MASH — that's a serious fatty-liver condition — then you are not eligible for the Bridge. And that's not a punishment. It's the opposite. For those conditions, you can already get these drugs through your regular Part D plan. You don't need the Bridge, so the Bridge isn't for you.

The Bridge exists for one specific purpose: the weight-management use that Part D otherwise won't touch. If your regular plan already covers your medication for a diagnosis it recognizes, that's your road. The Bridge is only for the folks who were locked out.

I mention this because I've already heard from people worried they'd "lose" their diabetes coverage by asking about the Bridge. You won't. Different door, different key.

How the $50 Is Supposed to Work

When everything runs the way it's meant to, it's genuinely simple. Here's the flow:

1. Your prescriber confirms you meet the criteria and writes the prescription.
2. They send it to your pharmacy.
3. The pharmacy sends a prior-authorization request form back to your prescriber — usually within 24 to 72 hours, by electronic PA or fax.
4. Your prescriber completes the attestation (this is where they confirm your BMI at initiation and the rest).
5. The claim gets routed to the Bridge's own processor.
6. It's approved.
7. You pay $50 at pickup.

That fifty dollars is a flat copay for a 28- or 30-day supply, and it stays fifty no matter which phase of your Part D benefit you happen to be in. The Part D deductible doesn't apply. A few things to hold in mind, though, so there are no surprises: the $50 does not count toward your TrOOP or your annual out-of-pocket cap, and no low-income subsidy applies to it. If you want a refresher on how that cap works this year, I laid it out in our piece on the 2026 prescription drug cap — the Bridge just sits outside of it.

Why Eligible Seniors Are Being Turned Away in Week One

Now we come to Dolores. To the frown behind the counter. To the reason good, eligible people are being sent home empty-handed.

The Bridge runs outside the normal Part D billing flow. Think of it as its own separate lane. It goes through a central processor — managed by Humana — with its own billing identifiers, its own address in the system. And that address has a name, two of them really, that I want you to write down:

BIN 028918 and PCN MEDDGLP1BR.

You don't need to understand what those letters and numbers mean any more than you need to understand the plumbing to know your kitchen faucet. Here's what matters: the pharmacy's computer has to send your claim to that specific lane. If it sends the claim to your regular Part D plan instead — the way it sends nearly every other prescription — the claim bounces back rejected. Automatically. Instantly.

And here's the cruel part: that rejection is not a coverage denial. It's the system's way of saying "wrong lane, and by the way, the Bridge prior authorization needs to be done first." To the computer, it's a routing note. To a woman standing at the counter with exact change in her purse, it looks exactly like being told no.

The three most common reasons for a week-one turn-away, in plain terms:

• The claim went to the regular Part D plan instead of the Bridge processor. Wrong lane.
• The BMI on the form was filled in with the current number instead of the number at the time therapy started. Remember that wrinkle? It bites here.
• The form was simply incomplete. A missing attestation, a blank field.

None of these means you don't qualify. Every one of them is fixable. This is paperwork and plumbing, not a verdict on you.

Exactly What to Do If You're Turned Away

Keep this section. Fold the corner of the page, or have your daughter save it to her phone. When the counter says no, here is what you do.

1. Don't leave without the specific reason. Ask the pharmacist for the exact rejection message or code the system gave. "It didn't go through" is not enough. You want the actual reason on the screen.

1. Ask the pharmacist directly: "Was this claim submitted to BIN 028918, PCN MEDDGLP1BR?" Read it off this page if you need to. That single question tells a busy pharmacist you know the claim needs to go to the Bridge processor, not to your regular Part D plan. Half the time, that's the whole fix right there.

1. Call your prescriber's office and confirm the prior authorization was submitted and completed correctly — especially that the BMI reflects the number at the time therapy started, not today's.

1. If the prescriber's office can't resolve it, call 1-800-MEDICARE (1-800-633-4227). They can help you sort out whether the problem is routing, paperwork, or something else.

1. Remember you still have your standard Part D appeal rights. A rejection is very often a fixable routing or paperwork issue — not a final answer. Don't let anyone tell you the door is closed when it's really just stuck.

What I've found, in my years of working with families, is that the difference between the person who gets their medication and the person who gives up is rarely eligibility. It's persistence, and knowing the one right question to ask. Now you have the question.

A Few Real Situations

Let me put faces on this, because rules live differently once you see them walking around.

Vivian started Wegovy last spring at a BMI of 36. This July she went to refill it under the Bridge and got rejected. Her pharmacist, when she asked the BIN-PCN question, realized the claim had gone to her regular Part D plan by habit. He resubmitted it to the Bridge processor, the prior authorization her doctor had already completed came through, and she walked out at fifty dollars. Wrong lane, corrected in ten minutes.

Earl wanted the Bridge but takes his GLP-1 for Type 2 diabetes. He didn't need it at all — his regular Part D plan already covers his medication. The Bridge would've been a step sideways for him, not forward. His pharmacist explained it, and Earl kept right on with the coverage he had.

Pearl was eligible on paper — she'd begun therapy two years ago at a BMI of 38 — but the prior-authorization form her doctor's office faxed listed her current BMI of 33. The claim rejected. One phone call to her prescriber, a corrected form noting the BMI at initiation, and it went through the next day. She'd nearly given up after the first no. I'm so glad she called me instead.

Three people, three different snags, and not one of them was actually about whether they deserved the medication.

What It Costs, With and Without the Bridge

Sometimes the numbers do the persuading better than I can.

Without the Bridge, in 2026, Wegovy's list price runs around $1,350 a month, and Zepbound somewhere between $1,000 and $1,100. The manufacturers' own self-pay or cash prices come down considerably from there — roughly $149 to $449 a month depending on the drug and the dose, with Foundayo's self-pay starting around $149 at the lowest dose.

And the Bridge? Fifty dollars.

I don't say that to make anyone feel foolish for having gone without before. I say it because the gap between $1,350 and $50 is exactly the kind of gap that changes what's possible for a person on a fixed income. It's the difference between "someday" and "this month." If you want the fuller picture of how Medicare drug pricing is shifting right now, our rundown on negotiated drug prices sets the stage — the Bridge is one piece of a larger loosening.

What Happens When the Bridge Ends

I won't sugarcoat this, because you deserve to plan.

The Bridge expires December 31, 2027, and as of now there is no confirmed extension. Please don't assume it renews automatically — watch for updates from CMS instead, and take nothing for granted.

There is, however, a bit of good news traveling alongside it. Novo Nordisk has announced it will cut Wegovy's list price to $675 a month starting January 1, 2027. That's still a real number, not a small one, but it's roughly half of today's list — and it lands while the Bridge is still running, which gives you a window to think about the road after.

This is also a good moment for the kind of housekeeping I'm always nudging families toward. Circumstances change, and so do plans. If you haven't looked at your Part D coverage since the fall, a mid-year check on your plan is worth an afternoon — and if you've had a Medicare Advantage plan ending on you, that reshuffles everything, including how a program like this reaches you. Planning ahead is just another form of taking care of yourself, and the cost of aging well is real enough that thinking it through in advance is never wasted time.

Your Action Steps

When you're worried, a list helps. Here's yours.

1. Ask your doctor whether a Bridge-covered drug — Foundayo, Wegovy, or Zepbound KwikPen — is right for you, and whether you meet the BMI criteria at the time therapy started.
2. Confirm the prior authorization is submitted, and that the form uses your BMI at initiation, not today's number.
3. Before you drive to the pharmacy, ask the office to verify the claim will route to the Bridge processor: BIN 028918 / PCN MEDDGLP1BR.
4. At pickup, if you're rejected, get the exact reason, and ask the pharmacist whether the claim went to BIN 028918 / PCN MEDDGLP1BR or to your regular Part D plan.
5. If it's not resolved, call your prescriber's office, then 1-800-MEDICARE (1-800-633-4227).
6. Hold onto your appeal rights. A rejection is usually a fixable snag, not a final no.
7. Mark your calendar for the end of 2027, and keep an eye on CMS for whatever comes next.

For anything about your own eligibility, your prescriber and 1-800-MEDICARE are the real authorities — not a website, not a neighbor, and not even me. When in doubt, Medicare.gov and your own doctor are where you go.

A Word Before You Go

Dolores got her Wegovy. It took a second trip, one phone call to her doctor's office, and that one question at the counter about the right lane — but she got it, and she paid her fifty dollars, and she called me back with a lightness in her voice I hadn't heard in a while.

I tell you her ending because I don't want anyone reading this to mistake a first-week snag for a closed door. So much of what looks like rejection in this life is really just a form filled out wrong, a claim sent to the wrong place, a system that hasn't quite caught up to us yet. The medication is there. The program is real. And the fix is almost always within reach of one good question asked by someone who refuses to be quietly turned away.

We are not meant to walk this path alone — and you are not meant to sort this out by yourself at a crowded counter with people sighing behind you. Bring this page. Bring the numbers. Bring a stubborn streak. You are enough, and you have always been enough, to advocate for the care you deserve.